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Abstract Fully human antibodies from transgenic ani-
mals account for an increasing number of new therapeutics.
After immunization, diverse human monoclonal antibodies
of high affinity can be obtained from transgenic rodents,
while large animals, such as transchromosomic cattle, have
produced respectable amounts of specific human immu-
noglobulin (Ig) in serum. Several strategies to derive
animals expressing human antibody repertoires have been
successful. In rodents, gene loci on bacterial artificial
chromosomes or yeast artificial chromosomes were inte-
grated by oocyte microinjection or transfection of
embryonic stem (ES) cells, while ruminants were derived
from manipulated fibroblasts with integrated human chro-
mosome fragments or human artificial chromosomes. In all
strains, the endogenous Ig loci have been silenced by gene
targeting, either in ES or fibroblast cells, or by zinc finger
technology via DNA microinjection; this was essential for
optimal production. However, comparisons showed that
fully human antibodies were not as efficiently produced as
wild-type Ig. This suboptimal performance, with respect to
immune response and antibody yield, was attributed to
imperfect interaction of the human constant region with
endogenous signaling components such as the Iga/b in
mouse, rat or cattle. Significant improvements were
obtained when the human V-region genes were linked to
the endogenous CH-region, either on large constructs or,
separately, by site-specific integration, which could also
silence the endogenous Ig locus by gene replacement or
inversion. In animals with knocked-out endogenous Ig loci
and integrated large IgH loci, containing many human Vs,
all D and all J segments linked to endogenous C genes,
highly diverse human antibody production similar to nor-
mal animals was obtained.
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BAC Bacterial artificial chromosome
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D Diversity segment








YAC Yeast artificial chromosome
ZFN Zinc-finger nuclease
Introduction
The first fully human monoclonal antibodies (mAbs) have
been produced over 25 years ago by two parallel technol-
ogies: phage display, with selection of antigen-specific
binders from blood lymphocyte libraries, and transgenic
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mice, with integrated human immunoglobulin (Ig) loci
(Bruggemann et al. 1989a; Bruggemann and Neuberger
1996; McCafferty et al. 1990; Neuberger and Bruggemann
1997). In the transgenic approach, natural diversification
and selection are being exploited as integrated loci are
under the control of the animal’s immune system where
they can undergo normal processes of DNA rearrangement
and hypermutation. Interestingly, human or mouse, and
probably all mammalian Ig loci work in very similar ways,
which was confirmed in early experiments using a germ-
line-configured chimeric construct (Bruggemann et al.
1989a).
A challenge to the transgenic antibody technology was
the large size of the human Ig loci (Cook and Tomlinson
1995; Frippiat et al. 1995; Matsuda et al. 1993; Pallares
et al. 1999; Weichhold et al. 1993). Emphasis was on
inclusion of V genes, as many and as diverse as possible,
rather than, for example, all D segments or several C genes
for the H chain (reviewed in Bruggemann et al. 2007).
Early approaches used minigenes and even with a small
number of genes mAbs with good binding characteristics
could be obtained (Green et al. 1994; Taylor et al. 1994;
Wagner et al. 1994). Improvements in oocytes microin-
jection and the use of embryonic stem (ES) cells permitted
the integration of larger regions; first on plasmids and
cosmids (Bruggemann et al. 1991; Taylor et al. 1994), and
then on bacterial artificial chromosomes (BACs) and yeast
artificial chromosomes (YACs) (Davies et al. 1993; Men-
dez et al. 1997; Nicholson et al. 1999; Popov et al. 1999;
Wagner et al. 1996).
At the same time, various Ig knock-out (KO) lines were
derived, with lMT being the earliest mouse line with a
silenced IgH locus (Kitamura et al. 1991). Apart from
studying lymphocyte development and antibody expression
in mice without fully functional H- and/or L-chain loci,
these approaches aided human antibody expression from
introduced transgenic Ig loci significantly. Many silencing
strategies were successful: removal of the JH segments,
abolished DNA rearrangement (Chen et al. 1993a), delet-
ing all CH genes eliminated H chain expression and trans-
switching (Ren et al. 2004), the various Cj or Jj KOs and a
Ck KO silenced IgL expression (Chen et al. 1993b; San-
chez et al. 1994; Zou et al. 2003). Breeding regimes to
combine H- and L-chain KOs with human IgH and IgL
transloci produced multi-feature animals expressing con-
siderable levels of diverse fully human Ig.
The production of transgenic antibody repertoires, sim-
ilar or comparable to those in humans, requires diverse
rearrangement combined with high expression of human V,
(D) and J segments, ideally from a large gene pool. This
has been achieved only recently in rodent lines, not with
fully human constructs but chimeric Ig loci, where immune
responses similar to wild-type (WT) animals and diversity
comparable to recorded human antibody sequences were
found (Lee et al. 2014; Ma et al. 2013; Osborn et al. 2013).
In Fig. 1a, the human IgH locus with all VHs, Ds and JH
genes/segments is illustrated. Features of the various fully
human and chimeric IgH transloci, large and small, are
presented in Fig. 1b.
Fully Human Ig Transloci
Fully human transloci contain exclusively human V, (D), J
and C genes, while in chimeric human transloci human V,
(D) and J genes or regions have been linked to host (rat,
mouse or cattle) C genes. In many cases, the size of the
fully human Ig constructs assembled, for example, in
plasmids, cosmids or phages, limited the number of genes
that could be included as these vectors could only
accommodate regions below *100 kb. This meant that V
genes had to be gathered in close proximity, D and J seg-
ments were tightly linked and C genes had to be carefully
chosen. The result was poor expression from such mini-
gene constructs although several useful human antibodies
have been derived (Lonberg et al. 1994). The assembly of
larger constructs in YACs by homologous overlaps (Davies
and Bruggemann 1993; Davies et al. 1992; Popov et al.
1996), and subsequent introduction of YACs into ES cells
by spheroplast fusion or lipofection enabled the integration
of several hundred kb up to *1 Mb large human IgH and
IgL regions into the mouse genome (Choi et al. 1993;
Davies et al. 1993; Mendez et al. 1997; Nicholson et al.
1999; Popov et al. 1999). Introduction of human mini-
chromosomes by microcell-mediated chromosome transfer
established ES cell-derived mouse lines producing fully
human mAbs (Kuroiwa et al. 2002; Tomizuka et al. 2000)
and cattle, derived from manipulated fibroblasts, which
expressed considerable amounts of human polyclonal Ig
(Matsushita et al. 2014; Sano et al. 2013). However, the
production of fully human mAbs in transchromosomic
mice appeared to be less than 1 % (Tomizuka et al. 2000)
and only about 50 % of fully human IgG was identified in
transchromosomic cattle, often at quite reduced levels
(Matsushita et al. 2014). Although problems concerned
with trans-chromosome truncation, chimerism and trans-
mission stability have been addressed, these could not be
fully resolved (Kakeda et al. 2005). A solution, which
considerably improved expression and efficiency of
hybridoma production, was cross-breeding of IgH trans-
chromo mice with Igj XenoMouse (Ishida et al. 2002;
Mendez et al. 1997).
Despite the improvement and breeding with endogenous
KO lines, human antibody titers were still suboptimal or at
best variable and despite diverse V, D and J usage, class-
switching was frequently poor and hypermutation was
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relatively low (Bruggemann et al. 2007). A problem for
many academic researchers was that supposedly superior
transgenic animals, produced by companies, were not
generally available and little support was provided to
improve available lines or constructs once they had been
published or shown to work in principle. Nevertheless,
useful fully human IgM antibodies of reasonable affinity
against HIV (when converted to human IgG1) could be
retrieved even from lines carrying few V genes and lacking
class-switching (Pruzina et al. 2011).
Rearrangement and expression of human IgL loci was
achieved with mini-gene constructs assembled on plasmids
and also larger regions on BACs and YACs; these earlier
constructs have been extensively reviewed (Bruggemann
et al. 2007, 2014). A comparison of human Igj L-chain
transloci showed that various germline-configured regions,
from 15 kb to over 1 Mb, readily express serum Ig but that
larger regions, with naturally spaced genes, produce much
higher antibody yields (Xian et al. 1998). Several larger
fully human IgL loci were highly expressed even in a WT
background, which showed successful competition with the
endogenous L-chain loci. For example, an authentic 380 kb
human Igk YAC with 15 functional Vk genes produced
high antibody titers from diverse and hypermutated tran-
scripts (Nicholson et al. 1999; Osborn et al. 2013; Popov
et al. 1999). Thus, it can be concluded that large fully
human L-chain constructs can be expressed similar to WT
L-chain levels in transgenic animals (Ma et al. 2013;
Osborn et al. 2013).
Chimeric Human Ig Transloci
To ensure optimal physiological interaction of translocus-
encoded membrane Ig with endogenous components of
antigen-receptor associated polypeptides, it has been
speculated and later shown that chimeric constructs with
human VDJ linked to rodent CH are most efficient (Green
2014; Ma et al. 2013; Osborn et al. 2013; Pruzina et al.
2011). Strategies to link human IgH V genes, D and J
segments with mouse or rat CH genes made use of BAC
and YAC technology for (1) sub-cloning and joining large
regions to secure overlapping integration by DNA micro-




Human VH D JH LocusA
B
IgH constructs Size Animal Derivaon Expression/WT Endogenous V D J use References
complete human IgH locus on mini-chromosome and 
replacement of human Cμ by bovine Cμ >1 Mb cale ﬁbroblasts reduced yes
Sano et al. 2013;             
Matsushita et al. 2014
complete human IgH locus on mini-chromosome >1 Mb mouse ES cells variable yes Tomizuka et al. 2000            Kuroiwa et al. 2002
sequenal inseron of human V D J  in endogenous IgH ~1 Mb mouse ES cells normal no Murphy 2009; Green 2014; Murphy et al. 2014
complete human V D J region in endogenous IgH ~1 Mb mouse ES cells normal yes Lee et al. 2014
~1/2 of all human Vs with all human D J - rat CH ~520 kb rat microinjecon normal no Osborn et al. 2013;                           Ma et al. 2013




fully human IgH locus with Cμ and 1 Cγ ~1 Mb mouse ES cells reduced no Mendez et al. 1997
fully human mini loci with 2-5 Vs and  Cμ (+/-Cδ) <240 kb mouse ES cells, microinjecon reduced no
Bruggemann et al. 1991; Green et 
al. 1994; Wagner  et al. 1996; 
Nicholson et al. 1999       
fully human mini locus with 4 Vs, Cμ and 1 Cγ 80 kb mouse microinjecon reduced no Lonberg et al. 1994
ﬁrst chimeric human-mouse IgH mini-locus 25 kb mouse microinjecon reduced yes Bruggemann et al. 1989a
Fig. 1 Human IgH loci. a The complete VH, D and JH region from
the most 50 VH, IgHV3–74, to the most 30 JH segment, JH6, is
accommodated on *950 kb (Lefranc and Lefranc 2001). b Trans-
genic constructs and features. Animals were derived from
manipulated fibroblasts (cattle) or ES cells (mouse) and by DNA
microinjection (mouse and rat). In several lines, human Ig expression
appeared to be reduced. Endogenous VDJ use or H chain products
with non-human segments, such as mouse or cattle Vs, were obtained
in strains with leaky or incomplete endogenous KO
Arch. Immunol. Ther. Exp. (2015) 63:101–108 103
123
and (2) sequential site-specific integration of BACs with
human V and V-D-J regions upstream of mouse Cl by
gene targeting or recombinase-mediated exchange (Lee
et al. 2014; Murphy 2009). Human VHs are efficiently
rearranged in transgenic mammals and their linkage to
endogenous CH genes provides a flawless interplay with the
cellular signaling machinery. Combined interactions of the
many components that aid B cell receptor (BCR) signaling
(see: http://www.biocarta.com/genes/PathwayGeneSearch.
asp) secure efficient B cell activation with normal immune
responses. Endogenous CH genes will also allow optimal
physiological interactions necessary in the regulation of
immune responses by the various host Fc receptors (Nim-
merjahn and Ravetch 2007; Rowland et al. 2013).
Conventional transgenic technologies with DNA
microinjection into oocytes enable the integration of mul-
tiple BACs and large YACs. This allowed the insertion of
three linear and overlapping BAC regions with homolo-
gous end sequences 50 and 30, which provided about half of
all human V genes, all D and all J segments (Osborn et al.
2013). A comparison of independent founders carrying a
continuous region of over 500 kb randomly integrated
found high expression levels independent of the site of
integration. The conclusion derived from many chimeric
(human V D J, rat C) IgH, as well as fully human Igj and
Igk lines, is that antibodies obtained from multiple large
integrations at one position can be as efficiently expressed
as WT Ig if the constructs contain the necessary regulatory
sequences (Ma et al. 2013). Furthermore, multiple inte-
gration of microinjected DNA, i.e., several copies of the
same BAC or YAC, may well be advantageous as larger
gene pools with an increased number of available genes
could facilitate more extensive receptor editing (Liu et al.
2013; Nemazee and Weigert 2000; Ouled-Haddou et al.
2014; Zhang et al. 2003).
Considerable efforts have been made to integrate large
numbers and possibly all human VH, D and JH segments
upstream of mouse Cl (Green 2014; Lee et al. 2014;
Murphy 2009; Murphy et al. 2014). Lee et al. (2014)
showed that with site-specifically integrated WT and
mutated loxP sites, it was possible to provide a BAC
landing pad for adding human V-regions upstream of the
first endogenous C gene. This approach employed
sequential integration of modified BACs, which recon-
stituted or replaced the mouse VH-region with equivalent
human genes. The result was to reconstitute a near
authentic human VH-D-JH as well as Vj-Jj and Vk-Jk
region (Green 2014; Lee et al. 2014; Murphy 2009).
With these insertions, duplications or multimeric inte-
gration of the same BAC are barred, which ensures a
genuine V gene order and content. However, there has
been no indication that non-selected or random integra-
tion of large transloci was disadvantageous and choosing
particular founders (or combination of founders for IgH
and IgL) secured high expression and breeding to
homozygosity.
Integration of human L-chain V-J regions adjacent to the
mouse CL gene has also been shown to yield extensive
chimeric antibody repertoires, but reports explained that
endogenous L-chain rearrangements were not entirely
prohibited (Green 2014; Lee et al. 2014). In contrast,
randomly integrated fully human Igj or Igk transloci could
be cleanly expressed—without residual rodent Ig in KO
lines—and extensive levels and diversity similar to WT
have been obtained (Osborn et al. 2013). This means that
there are no apparent advantages employing locus
replacement strategies in this instance.
Ig KO Strains
Ig loci have been knocked out or disabled in mouse, rat and
cattle (Bruggemann et al. 2007; Matsushita et al. 2014;
Osborn et al. 2013; Tomizuka et al. 2000). Strategies
involved gene targeting in ES cells via insertion or deletion
using, for example, Cre/loxP which allowed the removal of
[100 kb regions (Ren et al. 2004; Zou et al. 2003).
Recently, the use of zinc-finger (endo)nuclease (ZFN)
constructs for DNA microinjections into oocytes produced
several IgH and IgL KO lines in the rat (Geurts et al. 2009;
Menoret et al. 2010; Osborn et al. 2013) and silenced the
IgH locus in rabbits (Flisikowska et al. 2011). Advantages
of the ZFN technology are that non-homologous end
joining to silence a gene or locus via deletions up to several
kb can also provide a target site for homologous integration
(Cui et al. 2011).
More recently combined gene targeting and locus
extension have been taken to the next level. In one
approach where Cre recombinase was directed to opposite
loxP sites, integration was followed by inversion of the
mouse VH-D-JH region and, separately, Vj-Jj region (Lee
et al. 2014). This would not necessarily prevent DNA
rearrangement but with sufficient separation from C genes
splicing resulting in V(D)J-C products appeared to be
minimal (Lee et al. 2014). In another approach, deletion of
the whole V-region from both mouse IgH and Igj loci was
obtained (Green 2014).
A considerable advantage in expressing a human anti-
body repertoire in transgenic animals is the lack of all
endogenous Ig as this greatly simplifies the production of
polyclonal Ig, as shown in cattle (Matsushita et al. 2014),
and monoclonal Ig in rats (Osborn et al. 2013) and mice
(see: http://www.crescendobiologics.com/rnd/crescendo-
mouse). In these animals, no IgH, Igj and Igk with
endogenous V(D)J is being produced. The absence of
endogenous Ig prevents a bias in the immune response, for
104 Arch. Immunol. Ther. Exp. (2015) 63:101–108
123
example, selecting more compatible mouse idiotypes, and
means that selection and purification can be avoided.
Applications
mAb therapy has been developed to provide reagents that
specifically bind to cellular receptors or interact with cir-
culating targets for their removal or neutralization. Target
cell depletion can be achieved by Fc receptor interaction
and antibody-dependent cellular cytotoxicity has been
identified as an important mechanism to eliminate tumor
cells (Hjelm et al. 2006; Kim and Ashkenazi 2013; Mellor
et al. 2013). Binding of mAbs to particular cell-surface
receptors via the variable domain and simultaneously
engaging with natural killer cells, monocytes or macro-
phages via Fc receptor interaction provided by the constant
region (C region) initiates a cascade of events important for
removal or reduction of abnormal or malignant cells and
pathogens. In many epithelial tumors, epidermal growth
factor receptor is expressed at high levels and the tumor
cell load of many patients could be reduced with Vectibix
(see: http://www.vectibix.com). Tumor inhibition was also
achieved with anti-CD20 mAbs, which were effective in
initiating the destruction or killing of B cells from patients
with chronic lymphocytic leukemia, another very aggres-
sive disease (Zhang 2009).
Important validation for using transgenic lines includes
how well they compare with WT animals with respect to
serum titer, diversity and B cell development and if they
can be bred to homozygosity, which was achieved with
various rat and mouse strains. Success in DNA rearrange-
ment and antibody expression of the first construct
assembled in germline configuration (Bruggemann et al.
1989a) was followed by important progress regarding gene
targeting, to knock-out the mouse Ig loci, and genetic
engineering, to assemble large regions on artificial chro-
mosomes such as YACs (reviewed in Bruggemann 2001).
These advances were crucial to obtain specific, fully human
antibodies from the introduced human IgH (mini)loci
expressed in mice in the 1990s (Fishwild et al. 1996;
Lonberg et al. 1994; Mendez et al. 1997). However, none
of these early strains could match WT animals with regard
to B cell numbers, antibody titers, diversity and hyper-
mutation (Bruggemann et al. 2014; Green and Jakobovits
1998). Nevertheless, despite reduced expression levels,
antibodies from these early transgenic animals, in clinical
trials and on the market, have been obtained using
hybridoma technology (Green 2014). To overcome the
limitations of these first-generation strains, new transgenic
animals have been designed (Lee et al. 2014; Ma et al.
2013; Osborn et al. 2013).
FDA approved and marketed fully human mAbs pro-
duced from the early mouse strains are listed in Table 1.
The success of these mouse lines accelerated the shift from
using murine and chimeric antibodies to fully human
antibodies (reviewed in Bruggemann et al. 2014). Initially,
conventional immunization regimes and myeloma fusion
with spleen cells were adopted from procedures using WT
mice or rats (Kohler and Milstein 1975; Lachmann et al.
1980). However, in recently derived strains, mAb produc-
tion was significantly increased by the optimization of
immunization protocols. For example, fusions of mouse
myeloma cells with rat iliac lymph node cells collected
after rapid immunization schemes and, separately, spleen
cells obtained after multiple or booster immunizations,
frequently resulted in many thousand hybridomas from one
animal with sometimes over 100 diverse and high-affinity
IgGs (Osborn et al. 2013).
In 2014, a large number of defined (see: http://en.
wikipedia.org/wiki/List_of_monoclonal_antibodies) and
non-disclosed (see: http://biz.yahoo.com/e/130503/regn10-
q.html) fully human antibodies were being evaluated in
clinical trials. Close to 500 mAbs have been reported to be
in active clinical development during the past 3 years,
including *25 % in phase I, *40 % in phase II, *20 %
in phase III and *15 % at approval stage (BioPharm
Insight database). A large majority, *60 %, are indicated
primarily for treatment of cancer, e.g., reduction of solid
tumors possibly by blocking growth or inducing apoptosis.
Other therapeutic categories include immunological
(10 %), musculoskeletal (7 %) and infectious diseases
Table 1 FDA approved fully human therapeutic monoclonal antibodies
Year Name Target Treatment Transgenic line (references)
2011 Yervoy (ipilimumab) CTLA-4/CD152 Melanoma Lonberg et al. (1994)
2010 Prolia (denosumab) RANKL Osteoporosis Mendez et al. (1997)
2009 Simponi (golimumab) TNF-a Rheumatoid arthritis Lonberg et al. (1994)
2009 Arzerra (ofatumumab) CD20 Lymphocytic leukemia Fishwild et al. (1996)
2009 Stelara (ustekinumab) IL-12/IL-23 Psoriasis Lonberg et al. (1994)
2009 Ilaris (canakinumab) IL-1b Auto-inflammation Lonberg et al. (1994)
2006 Vectibix (panitumumab) EGFR Colorectal cancer Mendez et al. (1997)
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(4 %). Therapeutic antibodies are also being developed for
respiratory, dermatologic, central nervous system, hema-
tologic, eye/ear, cardiovascular, HIV, liver and other
diseases. Clinical-stage antibodies derived from transgenic
animals are shown in Table 2. Four distinct mouse lines
have been used to generate these: HuMAb antibody or
UltiMAb antibody Mouse (Lonberg et al. 1994), Xeno-
Mouse (Mendez et al. 1997), TransChromo Mouse (Ishida
et al. 2002) and VelocImmune Mouse (Murphy et al.
2014).
Different transgenic species are vitally important in pro-
viding human antibodies because of the trans-species gene
similarities. Thus, sequence comparison of rat, mouse and
human demonstrates that some genes are strikingly similar
and that the less similar animal provides the better immune
response. The other advantage of using different transgenic
species (e.g. rats and mice) is that their transgene usage
varies. As a result, many more genes from different families
yield antibodies of high affinity for the same antigen, which
may prove valuable for future immune therapy with mAb
Table 2 Promising fully human antibodies in clinical trials in 2014
Name Target Treatment Transgenic line (references)
Actoxumab/bezlotoxumab Clostridium difficile Clostridium difficile infection Lonberg et al. (1994)
Alirocumab Neural apoptosis-regulated proteinase 1 Hypercholesterolemia Murphy et al. (2014)
Anifrolumab IFN-a/b receptor Systemic lupus erythematosus Lonberg et al. (1994)
Brodalumab IL-17 Inflammatory diseases Mendez et al. (1997)
Conatumumab TNF-related apoptosis-inducing ligand Solid tumors
Cancers of hematopoietic origin
Mendez et al. (1997)
Daratumumab CD38 Multiple myeloma Lonberg et al. (1994)
Dupilumab IL-4Ra Allergic disease Murphy et al. (2014)
Eldelumab IFN-c-induced protein Crohn’s disease ulcerative colitis Lonberg et al. (1994)
Enoticumab DLL4 Solid tumors Murphy et al. (2014)
Evolocumab PCSK9 Hyperlipidemia Mendez et al. (1997)
Fulranumab NGF Pain Mendez et al. (1997)
Fasinumab Nerve growth factor Pain Murphy et al. (2014)
Ganitumab IGF-1 Cancer Mendez et al. (1997)
Guselkumab IL-13 Psoriasis Mendez et al. (1997)
Inclacumab Selectin P Cardiovascular disease Lonberg et al. (1994)
Intetumumab CD51 Solid tumors Murphy et al. (2014)
Iratumumab CD30 Hodgkin’s disease Lonberg et al. (1994)
Lirilumab KIR2D Solid tumors Lonberg et al. (1994)
Lucatumumab CD40 Lymphoma Mendez et al. (1997)
Necitumumab EGFR Non-small cell lung carcinoma Lonberg et al. (1994)
Nesvacumab Angiopoietin 2 Cancer Murphy et al. (2014)
Nivolumab PD-1 Cancer Lonberg et al. (1994)
Patritumab HER3 Non-small cell lung cancer Tomizuka et al. (2000)
REGN1033 Myostatin (GDF8) Metabolic disorders Murphy et al. (2014)
Rilotumumab HGF Solid tumors Mendez et al. (1997)




Mendez et al. (1997)
Teprotumumab IGF1R/CD221 Hematologic tumors Lonberg et al. (1994)
Ticilimumab/tremelimumab CTLA-4 Cancer Mendez et al. (1997)
Urelumab 4-1BB/CD137 Anti-tumor Lonberg et al. (1994)
Vantictumab Frizzled 7 receptor Solid tumors
Breast cancer
Murphy et al. (2014)
Zalutumumab EGFR Solid tumors Lonberg et al. (1994)
Zanolimumab CD4 T cell lymphoma Lonberg et al. (1994)
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mixtures. For example, high-affinity human antibodies have
recently been obtained from several other rodent lines;
OmniRat (Ma et al. 2013; Osborn et al. 2013) and Omni-
Mouse (http://www.omtinc.net), Kymouse (Lee et al. 2014)
and Harbour Mouse (http://harbourantibodies.com/science-
technology/h2l2/#.UyxGntzVvwI). Rabbits have also been
used to produce human antibodies (Flisikowska et al. 2011).
Novel antibodies with a common light chain have been
obtained from the MeMo mouse (http://www.merus.nl/
technology/memo.html) and OmniFlic (http://www.
openmonoclonaltechnology.com/antibody_technology.html)
lines. For therapeutic applications and minimizing immu-
nogenicity, endogenous C regions can be easily replaced by
the desired isotype without compromising antigen specific-
ity (Bruggemann et al. 1989b; Presta 2006).
Conclusions
Human antibodies produced in transgenic animals repre-
sent an important, broad and rapidly growing therapeutic
class with a predicted global market reaching many billion
US dollars (http://www.marketresearch.com). The success
is based on a now proven technology with DNA insertion
of Ig loci into the germline followed by expression of
human antibody repertoires. Transgenic animals are
increasingly used to produce antibodies with fully human
idiotypes, a trend that is expected to continue in years to
come as described in reports by The Times and BBC news
(both June 3, 2014) as ‘‘trials show they are fulfilling their
promise fast’’.
Significant improvements have been made recently with
the derivation of transgenic rat and mouse lines that, after
immunization, readily produce diverse high-affinity anti-
bodies as efficiently as WT animals (Osborn et al. 2013).
World-leading biopharmaceutical companies are now using
these animals to generate future human therapeutic anti-
bodies for a wide range of conditions.
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